marstacimab: Clinical Trials

5 completed, 4 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1, 3 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 2, Recruiting 1, Terminated 1
Phase 3	3	Recruiting 2, Completed 1
Phase 2	2	Completed 2

Follow marstacimab: new trials by email Literature Review of marstacimab trials Research Report on marstacimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Learn About the Study Medicine (Called Marstacimab) in People With Hemophilia A or B Marstacimab - Hemophilia		Not yet recruiting	Pfizer	100	2026-10-05	2026-10-05
Adult and Adolescent Hemophilia Patients Treated With Marstacimab: a Patient Experience Registry Marstacimab - Hemophilia		Recruiting	Institute of Hematology & Blood Diseases Hospital, China	100	2026-02-15	2026-04-29
A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan. Marstacimab - Hemophilia A or B		Active not recruiting	Pfizer	50	2025-10-30	2026-08-27
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. MARSTACIMAB - Severe Hemophilia A	Phase 1	Recruiting	Pfizer	15	2025-05-13	2026-10-15
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B marstacimab - Hemophilia A, Hemophilia B	Phase 3	Recruiting	Pfizer	100	2022-12-09	2026-10-14
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors PF-06741086 - Hemophilia A, Hemophilia B	Phase 3	Recruiting	Pfizer	245	2021-11-17	2026-07-01
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia PF-06741086 - Severe Hemophilia	Phase 1	Completed	Pfizer	6	2021-04-16	2023-07-07
A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device Marstacimab PFP, Marstacimab PFS - Healthy Volunteers	Phase 1	Terminated	Pfizer	22	2021-03-30	2022-07-11
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B PF-06741086 - Hemophilia A, Hemophilia B	Phase 3	Completed	Pfizer	188	2020-03-09	2026-08-14
PF-06741086 Long-term Treatment in Severe Hemophilia PF-06741086 - Hemophilia A or B	Phase 2	Completed	Pfizer	20	2018-05-30	2021-07-27
PF-06741086 Multiple Dose Study in Severe Hemophilia PF-06741086 - Hemophilia A or B	Phase 2	Completed	Pfizer	27	2017-03-08	2019-12-04
Dose Escalation Study of PF-06741086 In Healthy Subjects PF-06741086, Placebo - Healthy	Phase 1	Completed	Pfizer	41	2015-08-01	2016-08-12

Conditions studied

Hemophilia A (11)  ·  Hemophilia B (4)  ·  Hemorrhage (2)

Sponsors

Pfizer (11)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)

Countries

United States (6)  ·  China (5)  ·  South Africa (5)  ·  Croatia (4)  ·  India (4)  ·  Japan (4)  ·  Turkey (Türkiye) (4)  ·  Brazil (3)  ·  Canada (3)  ·  Italy (3)  ·  Mexico (3)  ·  South Korea (3)  ·  Spain (3)  ·  Taiwan (3)  ·  Argentina (2)

Results publications

PMID 42698050, PMID 35999026, PMID 36220152, PMID 40608864, PMID 41351884

NIH funding

2015 (1), 2016 (1), 2017 (1), 2018 (1)